Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy.

被引：4
|
作者：
Wang-Gillam, Andrea
Hubner, Richard
Mirakhur, Beloo
de Jong, Floris A.
Belanger, Bruce
Chen, Li-Tzong
机构：
[1] Washington Univ, Sch Med St Louis, St Louis, MO USA
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[4] Shire GmbH, Zug, Switzerland
[5] Ipsen Biosci Inc, Cambridge, MA USA
[6] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.388
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Siveke, Jens T.
    Mirakhur, Beloo
    Chen, Jie
    de Jong, Floris A.
    JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (03) : 427 - 435
  • [32] Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI ±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
    Jean-Frederic, Blanc
    Richard, Hubner
    Li Chung-Pin
    Andrea, Wang-Gillam
    Gyorgy, Bodoky
    Andrew, Dean
    Shan Yan-Shen
    Gayle, Jameson
    Teresa, Macarulla
    Kyung-Hun, Lee
    David, Cunningham
    Chiu Chang-Fang
    Gilberto, Schwartsmann
    Fadi, Braiteh
    Daniel, Von Hoff
    Chen Li-Tzong
    Khalid, Mamlouk
    Parul, Bhargava
    Floris, de Jong
    Jens, Siveke
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    Li, Chung-Pin
    Wang-Gillam, Andrea
    Bodoky, Gyorgy
    Dean, Andrew Peter
    Shan, Yan-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [34] The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV.
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Lee, Kyung-Hun
    Cunningham, David
    Hubner, Richard
    Braiteh, Fadi S.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris A.
    Mody, Purvi D.
    Von Hoff, Daniel D.
    Siveke, Jens T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)
    Weinberg, B.
    He, A.
    Tan, B.
    Turk, A.
    Noel, M.
    Marshall, J.
    Sung, M.
    Wang, H.
    Ferguson, C.
    Swanson, N.
    Pedersen, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S97 - S98
  • [36] Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study
    Melisi, D.
    Melisi, D.
    Siveke, J. T.
    Blanc, J.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L.
    Becker, C.
    Mamlouk, K.
    De Jong, F.
    Hubner, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Multicenter randomized phase II trial of 5-fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial
    Yoo, C.
    Jeong, J. H.
    Kim, K-P.
    Cheon, J.
    Kim, I.
    Kang, M.
    Ryu, H.
    Kang, B. W.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] POTENTIATION OF 5-FLUOROURACIL (5-FU) ANTI-METABOLIC EFFECT BY LEUCOVORIN (LV)
    WAXMAN, S
    BRUCKNER, H
    WAGLE, A
    SCHREIBER, C
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 149 - 149
  • [39] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [40] Trimetrexate (TMTX) modulation of 5-fluorouracil leucovorin (5-FU/LV) for advanced colorectal cancer
    Blanke, C
    Kasimis, B
    Schein, P
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 748 - 748
12345